Background-Today, mutations in more than 30 different genes have been found to cause inherited cardiomyopathies, some associated with very poor prognosis. However, because of the genetic heterogeneity and limitations in throughput and scalability of current diagnostic tools up until now, it is hardly possible to genetically characterize patients with cardiomyopathy in a fast, comprehensive, and cost-efficient manner. Methods and Results-We established an array-based subgenomic enrichment followed by next-generation sequencing to detect mutations in patients with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). With this approach, we show that the genomic region of interest can be enriched by a mean factor of 2169 compared with the coverage of the whole genome, resulting in high sequence coverage of selected disease genes and allowing us to define the genetic pathogenesis of cardiomyopathies in a single sequencing run. In 6 patients, we detected disease-causing mutations, 2 microdeletions, and 4 point mutations. Furthermore, we identified several novel nonsynonymous variants, which are predicted to be harmful, and hence, might be potential disease mutations or modifiers for DCM or HCM. 
Introduction and steady improvement of next-generation sequencing (NGS) technologies recently have led to a dramatic increase in parallelism, and hence, sequencing throughput, overcoming limitations of traditional capillary sequencing. 14, 15 Until now, however, cost-efficient NGS for the diagnosis of inherited diseases has not entered clinical practice, especially because of a lack of efficient reduction of genomic complexity and established protocols. We and others have shown recently that microarray-based sequence enrichment is feasible and highly efficient before sequencing. 16 -20 Here, we established microarray-based target enrichment followed by SOLiD NGS for the comprehensive and costefficient genetic diagnosis of cardiomyopathies.
Methods

Patients and DNA Sample Preparation
All study participants gave written informed consent, and the study was approved by the Ethic Committee of the University of Heidelberg (Heidelberg, Germany). From each patient, 5 g of genomicCovaris AFA system (Covaris Inc; Woburn, MA) to a size of 100 to 300 bp, as judged by agarose gel electrophoresis. Preparation of the adaptor-ligated DNA library was performed according to the manufacturer's instructions (ABI SOLiD 3Gϩ platform; Applied Biosystems; Carlsbad, CA). The adaptor-ligated DNA library was loaded onto an agarose gel, and the size fractions of 200 to 400 bp were excised. Sample concentration and quality was assessed by spectrometry (Nanodrop 1000; Thermo Scientific; Waltham, MA).
Targeted Sequence Enrichment
For the sequence capture array design, current literature was accessed and gene sequences of interest retrieved from reference databases (http://www.ensembl.org and http://genome.ucsc.edu). In addition to known cardiomyopathy disease genes (Table 1) , we included 18 novel potential cardiomyopathy genes. The final microarray design covered the coding regions of 47 genes, in total, 0.273 Mb.
Light-activated in situ oligonucleotide synthesis was performed essentially as described, using a digital micromirror device (Texas Instruments; Dallas, TX) for light-directed activation on an activated microfluidic array consisting of a glass/silicon-glass sandwich (febit biomed gmbh; Heidelberg, Germany). 21 Each chip consisted of 8 physically separated arrays with 15 000 individual DNA oligonucleotide features, resulting in a total content of about 120 000 features. For enrichment of the 47 selected genes, 2 arrays were used as an enrichment matrix for each patient sample. Fifty oligonucleotidelong capture probes were distributed over the coding sequences, with an average 9-bp tiling density to target both sense and antisense strands in an alternating manner.
The adaptor-ligated genomic DNA library, which has been amplified by 2 to 12 polymerase chain reaction (PCR) cycles and 500 g RNA per sample (transferred from baker's yeast; buffered aqueous solution, 10.5 mg/mL, 5ϫ1 mL; Sigma-Aldrich; Bayern, Germany) were dried in a Speed-Vac and dissolved in Hybmix-4 (febit biomed), heated to 95°C for 5 minutes, and placed on ice. The probes on each microarray were denatured with water at 80°C, and 2 g of the sample mixture was injected automatically onto the biochip in the HybSelector (febit biomed). Hybridization was performed overnight for 16 hours at 50°C, with agitation of the sample. After hybridization, each array was washed twice with 6ϫ SSPE at room temperature and 0.5ϫ SSPE at 45°C. Each array was subsequently washed with 2 mL of SSPE at room temperature. Hybrid- ization and all washing steps were automated and carried out by HybSelector. To further improve the enrichment, a second cycle was carried out. For elution of the enriched samples, the biochip was inserted into a HybSelect elution holder, and the arrays were filled with 15 L elution reagent and incubated at 70°C for 30 minutes. Placing the eluates in a Speed-Vac for drying finalized the library preparation and enrichment process after Ͻ1 week.
Next-Generation Resequencing and Data Analysis
Sequencing was carried out on the ABI SOLiD 3Gϩ sequencing platform according to the manufacturer's instructions. Of each DNA library, 0.34 ng was loaded onto 1 flow cell. The emulsion-PCR (ePCR) generating template-covered beads was performed with 40 cycles. Data analysis was carried out using CLC Genomics Workbench version 3.7 (CLC bio; Aarhus, Denmark) and LUMA (febit biomed). The 50-bp sequence reads were mapped against the human genome (hg18) (http://genome.ucsc.edu), performing a global, gapped alignment with the following parameters: mismatch cost, 2; insertion cost, 3; deletion cost, 3; limit, 8. Nonspecific matches were ignored. Variants were detected using single-nucleotide polymorphism (SNP) and deletion-insertion polymorphism detection with the following parameters: minimum coverage, 8; minimum average quality, 20; minimum central quality, 25; maximum gap and mismatch count, 2; expected ploidy, 2; minimum variant frequency, 25. These parameters were empirically defined after testing different combinations on a training set consisting of SOLiD raw data obtained from sequencing normal controls. For the calculation of the enrichment factor, the following equation was used: EFϭ(OTR/ FR)ϫ(genome length/TR), where EF indicates enrichment factor; OTR, on-target reads; FR, quality filtered raw reads; genome length, total human genome length (hg18); and TR, target region. All called variants were compared against National Center for Biotechnology Information (NCBI) SNP Database (dbSNP) build 128 and the March 2010 pilot release (Utah residents with ancestry from northern and western Europe) of the 1000 Genomes project (http:// www.1000genomes.org) using custom software and the ANNOVAR annotation tool. 22 The complete process of library preparation, sequence enrichment, NGS, and bioinformatic analysis was completed within 14 days.
Mutation Detection Using Sanger Sequencing and Heteroduplex Analysis
For Sanger sequencing of the coding sequence of myosin-binding protein-3 (MYBPC3) and lamin A/C (LMNA) and for the validation of detected variants, genomic regions up to a length of Ϸ600 bp were amplified by PCR using a single primer pair. Larger exons were split into smaller, overlapping amplicons. Amplicons were sequenced by MWG-Biotech AG (Ebersberg, Germany). Heteroduplex analysis using denaturating gradient gel electrophoresis was performed as described previously. 23 The sequences of primers and amplicons used in this study are available on request.
In Silico Analysis of Novel Nonsynonymous Variants Using SIFT
SIFT (http://sift.jcvi.org) is a sequence homology-based tool that sorts intolerant from tolerant amino acid substitutions and predicts whether an amino acid substitution in a protein will be likely to produce a phenotypic effect. 24 A file containing hg18 and hg19 genomic coordinates and base pair substitutions of all identified novel nonsynonymous variants was used as an input resource for the SIFT genome tool.
Results
Targeted Subgenomic Enrichment Followed by NGS Leads to High Sequence Coverage of Cardiomyopathy Genes
Ten consecutive patients with primary cardiomyopathies (5 with HCM and 5 with DCM) were included. In all patients, the genetic pathogenesis was previously unknown. Main patient characteristics are shown in Table 2 .
To achieve sufficient sequence coverage of the genes of interest, we performed subgenomic enrichment using oligonucleotide microarrays (for a schematic overview, see Figure 1 ). Typically, about 0.7 ng of enriched genomic DNA were recovered from the pair of capture arrays from which 0.34 ng were used for NGS using the ABI SOLiD 3Gϩ sequencing platform. Each sequencing run produced about 3ϫ10 7 50-bplong sequence reads, corresponding roughly to 2ϫ10 9 bases of total sequence output per patient sample. Next, we analyzed the number of reads that covered the selected coding regions of cardiomyopathy disease genes. Over all patients, 6% to 40% of all filtered reads matched to the target region. The mean number of mappable reads to the region of interest (ROI) was 2 340 148. Mean depth of coverage over all samples was 412ϫ (rangeϭ34 to 1155; SEMϭ340) ( Figure  2 ). When taking the mean background depth of coverage into consideration, the ratio of the mean depth of coverage of the ROI to the mean depth of coverage of the background showed that samples were enriched by a factor of 2169 (rangeϭ1345-fold to 4556-fold; SEMϭ1149). The mean target coverage was 97Ϯ1%, demonstrating the high performance of the sequence capture approach. As an example for the efficiency of sequence enrichment, Figure 3 depicts the sequence coverage of part of the desmin gene (DES, MIM 125660) in all 10 patients, whereas Figure 4 shows a randomly selected example showing the sequence coverage of the large titin gene (TTN, MIM 188840; coding length, 100 272 bases). For a comprehensive summary of the obtained sequencing results, see also Table 3 .
Sequence Variants and Mutations Within Cardiomyopathy Genes Can Be Reliably Detected by NGS
All successfully mapped sequence reads were analyzed to detect sequence variants, including insertions and deletions. Variants were called automatically, generating a list of sequence variants compared with the reference sequence (hg18; http://genome.ucsc.edu/), which we had annotated with NCBI dbSNP build 128 and an internal database Figure 1 . Targeted capturing of selected genomic fragments using hybridization-based microarrays. Genomic DNA is sheared, fragment-ends are repaired, and sequencing adaptors for SOLiD NGS are attached. The genomic library is then hybridized to the oligonucleotide probes on a microfluidic array to bind specific DNA fragments. After washing away weakly bound unspecific fragments, the enriched library is eluted and transferred to NGS. comprising disease mutations derived from HCM and DCM mutation databases (http://angis.org.au/Databases/Heart/ and http://genepath.med.harvard.edu/ϳseidman/cg3/index.html). Additionally, all novel nonsynonymous variants were filtered against the March 2010 pilot release of the 1000 Genomes project. All together, 57 548 known or novel variants were detected in the 10 patients. Of these variants, 57 089 (99.2%) are predicted to be noncoding or synonymous, whereas 459 (0.8%) are nonsynonymous, leading to the exchange of 1 or more amino acids (Table 4) . We further detected 21 663 small insertions or deletions, of which 809 are located in the ROI. Of all variants, 64.3% were heterozygous, showing 2 alleles at a defined genomic position.
Using our mutation detection workflow, we identified in HCM patient ID3283 a heterozygous microdeletion TT47321263..47321264del within the coding region of myosinbinding protein-3 (MYBPC3) ( Figure 5A ). The deletion, which is known to cause HCM, leads to a frameshift starting at codon 412 (p.F412fs) and consecutively premature termination of protein translation. 25, 26 In a second patient with HCM (ID3107), we detected another deletion, CT47313209..47313210del within the MYBPC3 gene, which leads to a frameshift at codon 955 and premature termination of protein translation. [25] [26] [27] We further identified 2 myosin heavy chain-␤ (MYH7) missense mutations: G22971762A (exon 5) in HCM patient ID3180 ( Figure 6A ) and G22968054A in patient ID3482. The first MYH7 mutation is predicted to lead to the exchange of arginine with glutamine at position 143 (p.R143Q), whereas the second leads to the exchange of arginine by a cysteine (p.R453C). 28, 29 In DCM patient ID3336, we identified a known LMNA nonsense mutation (C154372340T) leading to premature termination of protein translation at amino acid position 321 (p.R321stop) ( Figure  6B ). 23, 30 We also detected a variant with uncertain pathogenicity within MYBPC3 (p.R326Q) in patient ID3307. 31 In summary, Shown are variants within the ROIs. Values in parenthesis represent the total number of variants. The potential damaging effect of novel nonsynonymous variants within the ROI on protein function was predicted using SIFT (http://sift.jcvi.org).
we detected in 6 patients a known disease mutation for HCM or DCM (Table 5) . To test the specificity of variant detection, we sequenced the genomic regions harboring the 6 detected mutations and 44 randomly selected variants (nϭ50). As shown in Table 6 and Figures 5 through 7 , we could successfully verify 6 (100%) of 6 disease mutations and, in total, 43 (86%) of 50 detected variants by capillary sequencing.
To address sensitivity of the presented approach, we screened the coding region with adjacent intronic sequences of MYBPC3 and LMNA by capillary sequencing. From the detected 49 variants, 47 (96%) also were identified by NGS. Only 2 heterozygous variants residing in the intronic region of MYBPC3 were not called by the SNP detection algorithm but were covered with 10 and 13 unique reads, respectively. Further analysis showed that lower-quality indices and not coverage prevented calling of these variants.
Detection of Novel Sequence Variants and Potential Cardiomyopathy Mutations
Besides the detected variants and known cardiomyopathy disease mutations, we identified several novel sequence variants, which are not listed in the NCBI dbSNP or mutation-specific databases. For the 4 patients with HCM in whom we identified a known disease-causing mutation, we detected 75 novel nonsynonymous variants possibly acting as disease modifiers. For 1 patient with HCM (ID3131) in whom we did not find a known mutation, we identified in MYH7 a heterozygous missense mutation T484C leading to the amino acid exchange p.Y162H ( Figure 7A ). Although this mutation is novel, a mutation at the same amino acid position (p.Y162C) is known to cause HCM. 32 For the 3 patients with DCM in whom we could not identify a known disease mutation, 58 novel nonsynonymous variants were detected, possibly causative for DCM. To bioinformatically identify variants that most likely act disease 
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causing, we performed in silico analysis using SIFT. From 188 novel nonsynonymous variants in the 10 patients (58 in patients with DCM without known mutation), 26 were predicted to be damaging (Table 4 ). For instance, we found a novel variant C209T in 1 patient with DCM (ID3236), leading to the amino acid exchange p.P70L in the integrinlinked kinase gene (ILK) ( Figure 7B ). Besides the predicted detrimental effect on protein function, this variant is not present in 500 control subjects screened by heteroduplex analysis and cosegregates within the pedigree of the index patient (online-only Data Supplement Figure 1 ).
Discussion
Cardiomyopathies are a genetically heterogeneous group of disorders, hindering comprehensive and affordable genetic diagnostics in clinical practice. 1, [3] [4] [5] [6] 8, 10 We established here high-throughput mutation screening in disease genes for HCM and DCM using microarray-based target enrichment followed by SOLiD NGS, allowing the accurate detection of sequence variants and mutations in multiple disease-relevant genetic loci in parallel.
Comprehensive genetic profiling of patients with cardiomyopathy is largely hindered by the timely and financial efforts needed to genetically screen all known disease genes. 11, 33 Genetic complexity of cardiomyopathies will increase even further because, especially for DCM, the majority of disease genes are not yet defined. 1 Sanger sequencing is currently the gold standard to detect sequence variants within disease genes; however, it faces limitations in throughput and automation. Over the past years, NGS methods have dramatically improved, allowing now the analysis of gigabases of sequence information in 1 single run. 34 However, in contrast to Sanger sequencing, NGS unselectively analyzes whole genomic DNA, resulting in millions of reads that do not cover the ROIs, in most cases the coding regions of disease genes. 20 To overcome unselective sequencing, we enriched known cardiomyopathy disease regions by microarray-based sequence capturing before NGS. By this approach, we were able to increase the mean depth of coverage of cardiomyopathy genes 2169-fold, allowing detailed and cost-efficient analysis of 1092 disease exons and adjacent intronic regions in 1 NGS run. Genomic regions with low complexity or GC-rich sequence stretches can be difficult to capture by target enrichment approaches, resulting in low sequence coverage of these ROIs. However, in our study, over all samples, only 3% of ROIs could not be covered, and 91% were covered with at least 10 reads, which allows reliable variant detection on the SOLiD platform. These results will improve even further by optimizing the synthesized capture probes, which usually increase ROI coverage and thereby close the remaining sequencing gaps. 20 Optimization of capture probes and workflow standardization is also likely to reduce interindividual variability of sequence enrichment.
As shown in this article, our target enrichment strategy leads in average to a mean ROI coverage of 412 reads, allowing the reliable detection of sequence variants with high accuracy. Because HCM and DCM show a significant overlap in disease genes, we analyzed genomic DNA from peripheral blood of 5 patients with HCM and 5 with DCM with the same assay, enriched 1092 exons, and identified 1891 sequence variants within these disease regions, of which 349 were nonsynonymous. As shown, we identified mutations in known disease genes in 4 (80%) of the 5 patients with HCM and in 2 (40%) of the 5 patients with DCM. Despite the small sample size, these detection rates are in the expected range for both disorders. To confirm the specificity of our results, we selected 50 variants, including the detected disease mutations, and confirmed their existence by Sanger capillary sequencing. Of all disease mutations, 100% could be confirmed, whereas 86% of all sequence variants, including deletions and insertions, were identified correctly. To address sensitivity, we Sanger sequenced the coding region of MYBPC3 and LMNA in all patients. As shown, our targeted NGS approach also provides good sensitivity (96%), concordant with previous studies using NGS. 19 Only 2 variants were missed by NGS, not because of insufficient coverage, but because of lower-quality indices of sequence reads, a matter likely to be resolved when optimizing variant detection parameters.
The costs of NGS are still substantial in terms of investment in equipment. Nonetheless, the cost per base is substantially lower than for Sanger sequencing, and high parallelism reduces the need for manual handling steps. Hence, the presented NGS-based testing approach seems already competitive in this regard. Although commercially available screening of 4 to 8 HCM/DCM genes usually costs Ͼ$4000, the presented approach cost less than $1800 and comprises 47 genes. 35 Furthermore, with the described workflow, test results are available within 2 weeks after blood is drawn from the patient for DNA extraction.
Although sequence variants within disease genes can be reliably detected by NGS, as pointed out herein, proving their disease causality by cosegregation or functional genomics is key to the genetic diagnosis of cardiomyopathies. 36, 37 The most pragmatic approach is to compare detected variants against mutation databases, which contain gene mutations already shown to be causative for the respective disease. 38 In our study, we identified within 6 patients with cardiomyopathy established disease-causing mutations. For instance, we identified 2 microdeletions within the MYBPC3 gene, predictably leading to a frameshift and premature termination of protein translation. [25] [26] [27] The detection of insertions and deletions in NGS data has proven to be generally more difficult, particularly because of the relatively short read length typical for most platforms. Accordingly, the false-positive rate of detected insertions and deletions is considerably higher in our study compared to single-nucleotide variations. Here, the combination of paired-end sequencing and advanced assembly and insertion and deletion detection algorithms will further improve performance, although possibly not to levels of sensitivity and specificity that are achievable for single-nucleotide variations. 39 However, insertions and deletions are still more difficult to detect by other novel genetic testing approaches, such as hybridization-based sequencing chips. 40, 41 Recent studies identified numerous patients with cardiomyopathy who have more than 1 disease-causing mutation. [42] [43] [44] These mutations can occur in either the same gene (compound heterozygotes) or in different genes (double heterozygotes) in up to 5% of genetic cardiomyopathies. 45 As a consequence of these complex genotypes, the individual risk to develop end-stage disease or sudden cardiac death can strongly increase. 43, 44 As shown, we identified in all patients with HCM and DCM a disease-causing mutation as well as several novel sequence variants that might influence disease onset or progression. However, proving the disease causality of these potential mutations remains challenging. Using bioinformatic tools such as SIFT, one can predict harmful variants under the premise that protein evolution is correlated with protein function. Hence, variants changing conserved residues are more likely to alter or disrupt protein function. 24 Using SIFT, we could significantly reduce the number of novel nonsynonymous variants that may be disease related. For instance, we found the heterozygous missense mutation Y162H in HCM patient ID3131. Although this mutation is novel, a mutation affecting the same amino acid, Y162C, is known to cause HCM. It was suggested that tyrosine-162 is important for myosin ATPase activity because the tyrosine-162 and glycine-258 are opposite to each other in a domaindomain interface that might be affected when myosin cyclically interacts with actin and ATP. 32 We also detected a novel nonsynonymous variant p.P70L in the ILK gene in a patient with DCM with severely reduced left ventricular ejection fraction. The 21-year-old daughter carrying the same mutation shows a moderately decreased left ventricular ejection fraction. However, as mentioned previously, interpretation of disease contribution remains difficult. From a standpoint of statistical significance, large numbers of cases and controls have to be analyzed to ensure significant associations. 46 Here, deep-resequencing projects like the 1000 Genomes project ambitiously aim to provide more detailed maps of human genetic variation through genotyping at least 1000 human genomes from worldwide populations using NGS technologies. 47 These data will further help to distinguish rare, but benign variants from disease-causing mutations. Additionally, animal models, such as genetically manipulated mice or zebrafish, will contribute to a deeper understanding of the effects of novel sequence variants and compound heterozygosity. 45,48 -52 In summary, the presented staged procedure using microarray-based sequence enrichment followed by NGS allowed us to detect cardiomyopathy-causing mutations with high accuracy in a fast and cost-efficient manner that will be suitable for daily clinical practice of genetic testing. Combining our approach with multiplexing NGS will reduce the costs even further for comprehensive diagnosis of multigenic diseases. 53 As pointed out herein, rapid detection of novel gene variants has to be accompanied by additional strategies proving their disease causality.
